Iressa CAS NO.184475-35-2

After oral, effective oral absorption and metabolism of slower. A single oral bioavailability of 250 mg of close to 60%, medication in the area under the curve (AUC) was dose related. 1 times per day, after the treatment with 7 ~ 10 days of steady blood drug concentration, peak plasma concentration in 3 ~ 7 hours after the administration, then the blood drug concentration in two phase gradually reduce (half decayed for 12 ~ 58 hours, an average of 28 hours), and characterized by dose dependent pharmacokinetic, namely with multiple dosing, AUC and Cmax is proportional to the increase, and when taken with food, a up its Cmax and AUC did not significantly reduced. Plasma protein combined rate of nearly 90%. The treatment for the liver metabolism through many ways, metabolic process is relatively complex, participate in the oxidative metabolism mainly cytochrome P450 enzyme system of CYP3A4, main metabolites of O - methyl content. Metabolites has nothing to do with the prototype drug pharmacology for use. Prototype drugs mainly through biliary drainage, and most of the metabolites by faeces, and the urinary excretion of dosage below 4%.